Analysts Anticipate Kala Pharmaceuticals Inc (NASDAQ:KALA) Will Announce Quarterly Sales of $3.08 Million

Brokerages expect Kala Pharmaceuticals Inc (NASDAQ:KALA) to report sales of $3.08 million for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for Kala Pharmaceuticals’ earnings, with the highest sales estimate coming in at $4.27 million and the lowest estimate coming in at $2.50 million. The firm is scheduled to report its next quarterly earnings report on Monday, March 9th.

On average, analysts expect that Kala Pharmaceuticals will report full-year sales of $7.99 million for the current year, with estimates ranging from $7.40 million to $9.17 million. For the next fiscal year, analysts forecast that the business will post sales of $29.61 million, with estimates ranging from $17.16 million to $46.39 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow Kala Pharmaceuticals.

Kala Pharmaceuticals (NASDAQ:KALA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.01). The company had revenue of $1.45 million during the quarter, compared to the consensus estimate of $3.56 million.

A number of equities analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $10.00 price target (down from $12.00) on shares of Kala Pharmaceuticals in a report on Monday, November 11th. Zacks Investment Research lowered shares of Kala Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, November 19th. Oppenheimer set a $9.00 price target on shares of Kala Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, Wedbush restated an “outperform” rating and issued a $51.00 price objective on shares of Kala Pharmaceuticals in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $17.85.

Shares of Kala Pharmaceuticals stock traded down $0.12 during trading hours on Friday, hitting $4.02. The company’s stock had a trading volume of 5,195 shares, compared to its average volume of 237,514. Kala Pharmaceuticals has a twelve month low of $3.24 and a twelve month high of $9.25. The firm has a fifty day moving average of $3.81 and a 200-day moving average of $4.74. The stock has a market cap of $144.72 million, a price-to-earnings ratio of -1.64 and a beta of 2.21. The company has a debt-to-equity ratio of 1.65, a quick ratio of 5.94 and a current ratio of 6.25.

A number of institutional investors have recently made changes to their positions in the stock. Bank of Montreal Can lifted its stake in Kala Pharmaceuticals by 148.5% in the second quarter. Bank of Montreal Can now owns 4,014 shares of the company’s stock worth $26,000 after acquiring an additional 2,399 shares during the last quarter. Greenwich Wealth Management LLC grew its stake in Kala Pharmaceuticals by 28.7% during the 2nd quarter. Greenwich Wealth Management LLC now owns 13,000 shares of the company’s stock worth $83,000 after buying an additional 2,900 shares during the last quarter. Parametric Portfolio Associates LLC increased its position in Kala Pharmaceuticals by 17.1% during the second quarter. Parametric Portfolio Associates LLC now owns 39,692 shares of the company’s stock worth $253,000 after buying an additional 5,806 shares during the period. Marshall Wace LLP purchased a new stake in Kala Pharmaceuticals in the first quarter valued at approximately $325,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in Kala Pharmaceuticals by 34.8% in the second quarter. Charles Schwab Investment Management Inc. now owns 51,405 shares of the company’s stock valued at $328,000 after buying an additional 13,271 shares during the last quarter. Institutional investors own 64.21% of the company’s stock.

Kala Pharmaceuticals Company Profile

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

Featured Story: What is a balanced fund?

Get a free copy of the Zacks research report on Kala Pharmaceuticals (KALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.